Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 in Autoimmune Diseases
NCT07203404Phase 1Recruiting
- Sponsor
- Bioheng Therapeutics
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in systemic lupus erythematosus (SLE), lupus nephritis (LN), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 5 more, sponsored by Bioheng Therapeutics. Primary endpoint: Incidence of adverse events (TEAEs), serious adverse events (SAEs), and adverse events of particular concern (AESI) at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
RD06-05
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)anti-glomerular basement membrane diseasemembranous nephropathy (MN)
Beyond the preview
Go deeper on NCT07203404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203404.